SCHEMBL3555128

SCHEMBL3555128

CC(=O)n1c(C)c(O)c2cc(Br)ccc21

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.49
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 1/20 0.41
PDGFRA P16234 1/20 0.40
CDK5 Q00535 1/20 0.40
TYRO3 Q06418 1/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
TSPO P30536 1/20 0.38
LMNA P02545 2/20 0.36
MCL1 Q07820 1/20 0.36
HTT P42858 1/20 0.36
PLA2G2A P14555 1/20 0.36
GSK3B P49841 3/20 0.36
KRAS P01116 1/20 0.35
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27617502 0.83 ALDH1A1 (0.45) BAZ2BALDH1A1SMN1; SMN2CA12CA9
SCHEMBL29865552 0.83 BAZ2B (0.56) BAZ2BALDH1A1SMN1; SMN2POLBPDGFRA
SCHEMBL14717080 0.83 BAZ2B (0.56) BAZ2BALDH1A1SMN1; SMN2POLBPDGFRA
SCHEMBL3556800 0.81 AKR1C3 (0.42) POLB
SCHEMBL3558589 0.78 MAPT (0.51) ALDH1A1POLBLMNAHTT
SCHEMBL3551923 0.78 BAZ2B (0.44) BAZ2BALDH1A1POLBTSPOLMNA
SCHEMBL3557610 0.76 POLB (0.66) ALDH1A1POLBLMNA
SCHEMBL9983145 0.75 POLB (0.70) BAZ2BALDH1A1POLBTSPOLMNA
SCHEMBL6420808 0.75 NPC1 (0.35) SMN1; SMN2POLBHTT
SCHEMBL6424738 0.74 CYP3A4 (0.36) BAZ2BPOLBCA12CA9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed
WO-2004048331-A1 N-ARYLALKYL-3-AMINOALKOXYINDOLES AND THEIR USE AS 5-HT LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT BAZ2B 1556/4885ALDH1A1 1943/4885SMN1; SMN2 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.